trending Market Intelligence /marketintelligence/en/news-insights/trending/r_xeT16e9naMpXTxjs-y8Q2 content esgSubNav
In This List

US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA expands coverage of AbbVie, Johnson & Johnson blood cancer drug

The U.S. FDA approved Imbruvica for the treatment of relapsed or refractory marginal zone lymphoma, a rare form of blood cancer.

The drug, which is jointly developed and commercialized by AbbVie Inc.'s Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech Inc., is already approved for patients with mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia blood cancers.